Literature DB >> 29247834

The KL-VS polymorphism of KLOTHO gene is protective against retinopathy incidence in patients with type 1 diabetes.

Bartosz Słomiński1, Monika Ryba-Stanisławowska2, Maria Skrzypkowska2, Jolanta Myśliwska2, Małgorzata Myśliwiec3.   

Abstract

BACKGROUND AND AIMS: KLOTHO is an anti-ageing circulating hormone involved in insulin signaling, inflammation and vascular homeostasis through its protective effects on the endothelium and antioxidant actions. The common functional "KL-VS" variant of the KLOTHO gene is reproducibly associated with longevity in humans. Large number of studies have evaluated close relationship between KLOTHO protein and diabetes but the association between KL-VS variant and retinopathy in type 1 diabetes mellitus (T1D) is unknown. Therefore, in the present study we examined the association between the KL-VS polymorphism and the risk of diabetic retinopathy (DR) in patients with T1D.
METHODS: We examined 400 patients with T1D and 350 healthy age-matched controls. The analysis concerned KL-VS polymorphism along with the levels of serum inflammatory (CRP, TNF-α) and anti-inflammatory (IL-10) markers, pro-angiogenic (angiogenin) and anti-angiogenic interferon gamma-induced protein 10 (IP-10) factors as well as adhesion molecules (ICAM-1, ICAM-3).
RESULTS: We did not find significant association between T1D and KL-VS alleles. However, we observed that the incidence of KL-VS genotype is lower in a group with retinopathy in comparison to diabetic patients without this complication. Moreover, we established that KL-VS carriers had the lowest levels of inflammatory markers, pro-angiogenic factors and adhesion molecules. Simultaneously, the KL-VS carriers had increased serum levels of anti-inflammatory and anti-angiogenic cytokines than holders bearing wild type genotype.
CONCLUSIONS: In conclusion, the findings of our studies suggest that the functional KL-VS variant of the KLOTHO gene protects against the development of retinopathy in patients with T1D.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diabetes retinopathy; Inflammation; KL-VS polymorphism

Mesh:

Substances:

Year:  2017        PMID: 29247834     DOI: 10.1016/j.bbadis.2017.12.015

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  5 in total

Review 1.  Klotho: An Elephant in Aging Research.

Authors:  Amin Cheikhi; Aaron Barchowsky; Amrita Sahu; Sunita N Shinde; Abish Pius; Zachary J Clemens; Hua Li; Charles A Kennedy; Joerg D Hoeck; Michael Franti; Fabrisia Ambrosio
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2019-06-18       Impact factor: 6.053

2.  Association of KLOTHO polymorphisms with clinical complications of sickle cell anemia.

Authors:  Jéssica V G F Batista; Diego A Pereira-Martins; Diego A Falcão; Igor F Domingos; Gabriela S Arcanjo; Betânia L Hatzlhofer; Isabel Weinhäuser; Thais H C Batista; Pablo R G Cardoso; Ana C Dos Anjos; Manuela F Hazin; Maira G R Pitta; Fernando F Costa; Aderson S Araujo; Antonio R Lucena-Araujo; Marcos A Bezerra
Journal:  Ann Hematol       Date:  2021-06-14       Impact factor: 3.673

3.  Protective potential of klotho protein on diabetic retinopathy: Evidence from clinical and in vitro studies.

Authors:  Baolan Ji; Huili Wei; Yao Ding; Huimin Liang; Lu Yao; Hang Wang; Hua Qu; Huacong Deng
Journal:  J Diabetes Investig       Date:  2019-07-20       Impact factor: 4.232

4.  A new potential mode of cardiorenal protection of KLOTHO gene variability in type 1 diabetic adolescents.

Authors:  Bartosz Słomiński; Monika Ryba-Stanisławowska; Maria Skrzypkowska; Magdalena Gabig-Cimińska; Małgorzata Myśliwiec
Journal:  J Mol Med (Berl)       Date:  2020-05-20       Impact factor: 4.599

5.  Low levels of circulating anti-ageing hormone Klotho predict the onset and progression of diabetic retinopathy.

Authors:  Antonella Corcillo; Nikolaos Fountoulakis; Angela Sohal; Frederick Farrow; Salma Ayis; Janaka Karalliedde
Journal:  Diab Vasc Dis Res       Date:  2020 Nov-Dec       Impact factor: 3.291

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.